AEON Biopharma Inc.
|Number of Estimates|
we are a nasdaq-listed special purpose acquisition company whose business purpose is to effect a merger or similar business combination with one or more businesses. our acquisition strategy is to identify and complete our initial business combination with a medical technology company in the healthcare industry. our sponsor team consists of chairman/ceo robert palmisano, president vikram malik, cfo oleg grodnensky and chief legal officer david meredith.
Market Cap: 12.3 Million
Primary Exchange: NYSE MKT LLC
Shares Outstanding: 9.2 Million
Dividend: 0.0 (0.0%)
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Longest drawdown: 42 trading days
From: 2023-07-31 To: 2023-09-28
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|